Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS: A RETROSPECTIVE COHORT STUDY

View ORCID ProfileFrancisco J. de Abajo, Antonio Rodríguez-Miguel, Sara Rodríguez-Martín, Victoria Lerma, Alberto García-Lledó
doi: https://doi.org/10.1101/2021.02.01.21250853
Francisco J. de Abajo
1Clinical Pharmacology Unit. University Hospital Príncipe de Asturias. Alcalá de Henares. Madrid. Spain
2Department of Biomedical Sciences (Pharmacology Section). University of Alcalá (IRYCIS). Alcalá de Henares. Madrid. Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francisco J. de Abajo
  • For correspondence: francisco.abajo@uah.es
Antonio Rodríguez-Miguel
1Clinical Pharmacology Unit. University Hospital Príncipe de Asturias. Alcalá de Henares. Madrid. Spain
2Department of Biomedical Sciences (Pharmacology Section). University of Alcalá (IRYCIS). Alcalá de Henares. Madrid. Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Rodríguez-Martín
1Clinical Pharmacology Unit. University Hospital Príncipe de Asturias. Alcalá de Henares. Madrid. Spain
2Department of Biomedical Sciences (Pharmacology Section). University of Alcalá (IRYCIS). Alcalá de Henares. Madrid. Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria Lerma
1Clinical Pharmacology Unit. University Hospital Príncipe de Asturias. Alcalá de Henares. Madrid. Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto García-Lledó
3Department of Cardiology, University Hospital Príncipe de Asturias. Alcalá de Henares. Madrid. Spain
4Department of Medicine, University of Alcalá (IRYCIS). Alcalá de Henares. Madrid. Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Several studies have reported a reduced risk of death associated with the inpatient use of angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) in COVID-19 patients, but have been criticized for incurring in several types of bias. Also, most studies have pooled ACEIs and ARBs as if they were a unique group, overlooking their pharmacological differences. We aimed to assess whether the in-hospital continuation of ARBs and ACEIs, in regular users of these drugs, was associated with a reduced risk of death as compared to their discontinuation and also to compare head-to-head ARBs with ACEIs.

Methods Adult patients with a PCR-confirmed diagnosis of COVID-19 requiring admission during March, 2020 were consecutively selected from 7 hospitals in Madrid, Spain. Among them, we identified outpatient users of ACEIs/ARBs and divided them in two cohorts depending on treatment discontinuation/continuation at admission. Then, they were followed-up until discharge or in-hospital death. An intention-to-treat survival analysis was carried out and hazard ratios (HRs) and their 95%CI were computed through a Cox regression model adjusted for propensity scores of discontinuation and controlled by potential mediators.

Results Out of 625 ACEI/ARB users, 340(54.4%) discontinued treatment. The in-hospital mortality rates were 27.6% and 27.7% in discontinuation and continuation cohorts, respectively (HR=1.01; 95%CI:0.70-1.46). No difference in mortality was observed between ARB and ACEI discontinuation (28.6% vs. 27.1%, respectively), while a significantly lower mortality rate was found among patients who continued with ARBs (20.8%,N=125) as compared to those who continued with ACEIs (33.1%,N=136; p=0.03). The head-to-head comparison (ARB vs. ACEI continuation) yielded an adjusted HR of 0.52 (95%CI:0.29-0.93), being especially notorious among males (HR=0.34; 95%CI:0.12-0.93), subjects older than 74 years (HR=0.46; 95%CI:0.25-0.85), and patients with obesity (HR=0.22; 95%CI:0.05-0.94), diabetes (HR=0.36; 95%CI:0.13-0.97) and heart failure (HR=0.12; 95%CI:0.03-0.97).

Conclusions Among regular users of ARBs admitted for COVID-19, the in-hospital continuation with them was associated with an improved survival, while this was not observed with ACEIs. Regular users of ARBs should continue with this treatment if admitted for COVID-19, unless medically contraindicated. In admitted ACEI users, a switching to ARBs should be considered, especially among high-risk patients.

Figure1
  • Download figure
  • Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding: This study is part of a larger project which received funding from the Instituto de Salud Carlos III (#COV20/00027). Additionally, the University of Alcala (#COVID-19 UAH 2019/00003/016/001/028) and the Biomedical Research Foundation from the University Hospital Principe de Asturias granted to FdA complementary grants for this project. The funding sources had no role in the study design, data collection, analysis and interpretation of data, writing of the report; and in the decision to submit the paper for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The present study was an extension of a previous study approved by the Ethics Research Committee of the University Hospital Principe de Asturias on March 18, 2020 (#SRAA-COVID19), including a waiver for the informed consent [6]. The Ethics Research Committee was informed of this extension, and no additional ethical assessment was required. Data extracted were fully anonymised and no attempt was made to interview patients or relatives. The study complied with the provisions of the European and Spanish legislation.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* MED-ACE2-COVID19 Study Group: Hospital Universitario Príncipe de Asturias: F J de Abajo, A Rodríguez-Miguel, S Rodríguez-Martín, V Lerma, A García-Lledó, D Barreira-Hernández; D Rodríguez-Puyol; Hospital Universitario de Getafe: O Laosa, L Pedraza, L Rodríguez-Mañas; Hospital Universitario Ramón y Cajal: M Aguilar, I de Pablo, MA Gálvez; Hospital Central de la Defensa Gómez Ulla: A García-Luque, M Puerro; RM Aparicio, V García-Rosado, C Gutiérrez-Ortega; Hospital Clínico San Carlos: L Laredo, E González-Rojano, C Pérez, A Ascaso, C Elvira; Hospital Universitario de La Princesa: G Mejía-Abril, P Zubiaur, E Santos-Molina, E Pintos-Sánchez, M Navares-Gómez; F Abad-Santos; Hospital Universitario Puerta de Hierro-Majadahonda: G A Centeno, A Sancho-Lopez, C Payares-Herrera, E Diago-Sempere.

Data Availability

Data sharing: After publication, the data will be made available to others on reasonable requests to the corresponding author. A proposal with detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. Deidentified participant data will be provided after approval from the principal researchers of the participating hospitals.

  • ABBEVIATIONS

    ACE1
    Angiotensin converting enzyme 1
    ACE2
    Angiotensin converting enzyme 2
    ACEIs
    Angiotensin-converting enzyme inhibitors
    AMRs
    Antagonists of mineralocorticoid receptor
    ARBs
    Angiotensin receptor blockers
    AT1R
    Receptor for angiotensin II type 1
    AT2R
    Receptor for angiotensin II type 2
    BMI
    Body mass index
    CCBs
    Calcium channel blockers
    CI
    Confidence interval
    COPD
    Chronic obstructive pulmonary disease
    COVID-19
    Coronavirus disease 19
    CPR
    C-protein reactive
    CV
    Cardiovascular
    ED
    Emergency Department
    HR
    Hazard ratio
    ICU
    Intensive care unit
    IQR
    Interquartile range
    ITT
    Intention-to-treat
    MC-HR
    Mediator-controlled hazard ratio
    NSAIDs
    Nonsteroidal anti-inflammatory drugs
    NT-pro-BNP
    N terminal pro-peptide of natriuretic factor type B
    OADs
    Other antihypertensive drugs different from RASIs or CCBs
    OR
    Odds ratio
    PS
    Propensity scores
    PS-adjusted HR
    Propensity score adjusted hazard ratio
    RASIs
    Renin-angiotensin system inhibitors
    SD
    Standard deviation
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted February 03, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS: A RETROSPECTIVE COHORT STUDY
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS: A RETROSPECTIVE COHORT STUDY
    Francisco J. de Abajo, Antonio Rodríguez-Miguel, Sara Rodríguez-Martín, Victoria Lerma, Alberto García-Lledó
    medRxiv 2021.02.01.21250853; doi: https://doi.org/10.1101/2021.02.01.21250853
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS: A RETROSPECTIVE COHORT STUDY
    Francisco J. de Abajo, Antonio Rodríguez-Miguel, Sara Rodríguez-Martín, Victoria Lerma, Alberto García-Lledó
    medRxiv 2021.02.01.21250853; doi: https://doi.org/10.1101/2021.02.01.21250853

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Pharmacology and Therapeutics
    Subject Areas
    All Articles
    • Addiction Medicine (70)
    • Allergy and Immunology (168)
    • Anesthesia (50)
    • Cardiovascular Medicine (451)
    • Dentistry and Oral Medicine (83)
    • Dermatology (55)
    • Emergency Medicine (157)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
    • Epidemiology (5258)
    • Forensic Medicine (3)
    • Gastroenterology (195)
    • Genetic and Genomic Medicine (757)
    • Geriatric Medicine (80)
    • Health Economics (213)
    • Health Informatics (698)
    • Health Policy (358)
    • Health Systems and Quality Improvement (224)
    • Hematology (99)
    • HIV/AIDS (163)
    • Infectious Diseases (except HIV/AIDS) (5872)
    • Intensive Care and Critical Care Medicine (362)
    • Medical Education (104)
    • Medical Ethics (25)
    • Nephrology (83)
    • Neurology (764)
    • Nursing (43)
    • Nutrition (130)
    • Obstetrics and Gynecology (142)
    • Occupational and Environmental Health (233)
    • Oncology (479)
    • Ophthalmology (152)
    • Orthopedics (39)
    • Otolaryngology (95)
    • Pain Medicine (39)
    • Palliative Medicine (20)
    • Pathology (141)
    • Pediatrics (223)
    • Pharmacology and Therapeutics (136)
    • Primary Care Research (96)
    • Psychiatry and Clinical Psychology (862)
    • Public and Global Health (2012)
    • Radiology and Imaging (348)
    • Rehabilitation Medicine and Physical Therapy (158)
    • Respiratory Medicine (285)
    • Rheumatology (94)
    • Sexual and Reproductive Health (74)
    • Sports Medicine (76)
    • Surgery (109)
    • Toxicology (25)
    • Transplantation (29)
    • Urology (39)